Erratum: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy (Glob Region Health Technol Assess (2021) 8 (69-79) DOI: 10.33393/grhta.2021.2267)

Abstract

In the article "Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy", (1) which appeared in Volume 8, Issue 1 of Global & Regional Health Technology Assessment, the values appearing in Fig. 5 C and D, inadvertently repeated the values reported in Fig. 5 A and B. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study. The final version of this article is available online and includes a reference to this correction.